Skip to main content
Top
Published in: Clinical and Translational Oncology 8/2019

Open Access 01-08-2019 | Breast Cancer | Research Article

Cause-specific mortality after a breast cancer diagnosis: a cohort study of 10,195 women in Girona and Tarragona

Authors: A. Ameijide, R. Clèries, M. Carulla, M. Buxó, R. Marcos-Gragera, J. M. Martínez, M. L. Vilardell, M. Vilardell, J. A. Espinàs, J. M. Borràs, Á. Izquierdo, J. Galceran

Published in: Clinical and Translational Oncology | Issue 8/2019

Login to get access

Abstract

Introduction

Evidence suggests an excess of long-term mortality due to cardiovascular diseases, second tumours and other causes in patients diagnosed with invasive breast cancer (BC). Our aim was to assess this risk of death in a cohort of patients diagnosed with BC in Girona and Tarragona, northeastern Spain.

Materials and methods

Using data from the cancer registries in these areas, a population-based cohort study was carried out including all the women diagnosed with BC during 1985–2004 and followed up until December 31st 2014 (N = 10,195). The standardised mortality ratios (SMRs) were calculated for causes other than BC in the cohort at 10 years (periods 1985–1994/1995–2004) and 20 years (period 1985–1994). The impact of competing causes of death in the long-term survival was evaluated through competing risk analysis.

Results

The SMRs at 10 and 20 years for all-cause mortality, except BC, were 1.21 and 1.22. The main causes of mortality showing statistically significant SMR at 10 years were other tumours (colon, lung, corpus uteri, ovary, and haematological), diabetes mellitus, diseases of the nervous system, cardiovascular diseases (after BC, the second competing cause of death among patients diagnosed > 69 years) and diseases of the kidney. Globally, the 10-year SMR was higher in the first period. After 20 years of follow-up (1985–1994 cohort), there were 48.5 excess deaths per 10,000 patient-years for causes other than BC.

Conclusions

Women who did not die from BC at 10 or 20 years after the BC diagnosis had 20% higher risk of dying from other causes than women without BC. This excess risk must be clinically considered during 20 years after the BC diagnosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.CrossRef
2.
go back to reference Galceran J, Ameijide A, Carulla M, Mateos A, Quiros JR, Rojas D, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 2017;19(7):799–825.CrossRef Galceran J, Ameijide A, Carulla M, Mateos A, Quiros JR, Rojas D, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 2017;19(7):799–825.CrossRef
3.
go back to reference Chirlaque MD, Salmerón D, Galceran J, Ameijide A, Mateos A, Torrella A, et al. Cancer survival in adult patients in Spain. Results from nine population-based cancer registries. Clin Transl Oncol. 2018;20(2):201–11.CrossRef Chirlaque MD, Salmerón D, Galceran J, Ameijide A, Mateos A, Torrella A, et al. Cancer survival in adult patients in Spain. Results from nine population-based cancer registries. Clin Transl Oncol. 2018;20(2):201–11.CrossRef
4.
go back to reference Crocetti E, Roche L, Buzzoni C, di Costanzo F, Molinié F, Caldarella A, et al. Trends in net survival from breast cancer in six European Latin countries: results from the SUDCAN population-based study. Eur J Cancer Prev. 2017;26:S85–91.CrossRef Crocetti E, Roche L, Buzzoni C, di Costanzo F, Molinié F, Caldarella A, et al. Trends in net survival from breast cancer in six European Latin countries: results from the SUDCAN population-based study. Eur J Cancer Prev. 2017;26:S85–91.CrossRef
5.
go back to reference Overgaard M, Jensen M. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cooperative Group DBCG 82c randomized trial. Lancet. 1999;353:1641–848.CrossRef Overgaard M, Jensen M. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cooperative Group DBCG 82c randomized trial. Lancet. 1999;353:1641–848.CrossRef
6.
go back to reference Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365(9472):1687–717.CrossRef Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365(9472):1687–717.CrossRef
7.
go back to reference Allemani C, Minicozzi P, Berrino F, Bastiaannet E, Gavin A, Galceran J, et al. Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000–2002. Int J Cancer. 2013;132(10):2404–12.CrossRef Allemani C, Minicozzi P, Berrino F, Bastiaannet E, Gavin A, Galceran J, et al. Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000–2002. Int J Cancer. 2013;132(10):2404–12.CrossRef
8.
go back to reference Early Breast Cancer Trialists’ Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Lancet. 2000;355:1757–70.CrossRef Early Breast Cancer Trialists’ Collaborative Group. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Lancet. 2000;355:1757–70.CrossRef
9.
go back to reference Roychoudhuri R, Robinson D, Putcha V, Cuzick J, Darby S, Møller H. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. BMC Cancer. 2007;15(7):9.CrossRef Roychoudhuri R, Robinson D, Putcha V, Cuzick J, Darby S, Møller H. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study. BMC Cancer. 2007;15(7):9.CrossRef
10.
go back to reference Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD. Cardiovascular disease mortality among breast cancer survivors. Epidemiology. 2016;27(1):6–13.CrossRef Bradshaw PT, Stevens J, Khankari N, Teitelbaum SL, Neugut AI, Gammon MD. Cardiovascular disease mortality among breast cancer survivors. Epidemiology. 2016;27(1):6–13.CrossRef
11.
go back to reference Hooning MJ, Aleman BMP, van Rosmalen AJM, Kuenen MA, Klijn JGM, van Leeuwen FE. Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study. Int J Radiat Oncol Biol Phys. 2006;64(4):1081–91.CrossRef Hooning MJ, Aleman BMP, van Rosmalen AJM, Kuenen MA, Klijn JGM, van Leeuwen FE. Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study. Int J Radiat Oncol Biol Phys. 2006;64(4):1081–91.CrossRef
12.
go back to reference Clèries R, Ameijide A, Buxó M, Martínez JM, Marcos-Gragera R, Vilardell ML, et al. Long-term crude probabilities of death among breast cancer patients by age and stage: a population-based survival study in Northeastern Spain (Girona-Tarragona 1985–2004). Clin Transl Oncol. 2018;20(10):1252–60.CrossRef Clèries R, Ameijide A, Buxó M, Martínez JM, Marcos-Gragera R, Vilardell ML, et al. Long-term crude probabilities of death among breast cancer patients by age and stage: a population-based survival study in Northeastern Spain (Girona-Tarragona 1985–2004). Clin Transl Oncol. 2018;20(10):1252–60.CrossRef
13.
go back to reference Breslow NE, Day NE. Statistical methods in cancer research. Volume II—the design and analysis of cohort studies. IARC Sci Publ. 1987;82:1–406. Breslow NE, Day NE. Statistical methods in cancer research. Volume II—the design and analysis of cohort studies. IARC Sci Publ. 1987;82:1–406.
14.
go back to reference Colzani E, Liljegren A, Johansson AL, Adolfsson J, Hellborg H, Hall PF, et al. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumour characteristics. J Clin Oncol. 2011;29(30):4014–21.CrossRef Colzani E, Liljegren A, Johansson AL, Adolfsson J, Hellborg H, Hall PF, et al. Prognosis of patients with breast cancer: causes of death and effects of time since diagnosis, age, and tumour characteristics. J Clin Oncol. 2011;29(30):4014–21.CrossRef
15.
go back to reference Taylor CW, Povall JM, McGale P, Nisbet A, Dodwell D, Smith JT, et al. Cardiac dose from tangential breast cancer radiotherapy in the year 2006. Int J Radiat Oncol Biol Phys. 2008;72(2):501–7.CrossRef Taylor CW, Povall JM, McGale P, Nisbet A, Dodwell D, Smith JT, et al. Cardiac dose from tangential breast cancer radiotherapy in the year 2006. Int J Radiat Oncol Biol Phys. 2008;72(2):501–7.CrossRef
16.
go back to reference Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935–82. Natl Cancer Inst Monogr. 1985;68:99–112.PubMed Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935–82. Natl Cancer Inst Monogr. 1985;68:99–112.PubMed
17.
go back to reference de Gonzalez AB, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer. 2010;102:220–6.CrossRef de Gonzalez AB, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer. 2010;102:220–6.CrossRef
18.
go back to reference Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.CrossRef Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans E, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;366:2087–106.CrossRef
19.
go back to reference Borràs JM, Piñol JL, Izquierdo A, Borràs J. Analysis of cancer incidence, survival and mortality according to the main tumoural localizations, 1985–2019: lung cancer. Med Clin (Barc). 2008;131(Suppl 1):53–7.CrossRef Borràs JM, Piñol JL, Izquierdo A, Borràs J. Analysis of cancer incidence, survival and mortality according to the main tumoural localizations, 1985–2019: lung cancer. Med Clin (Barc). 2008;131(Suppl 1):53–7.CrossRef
20.
go back to reference Huang J, Mackillop WJ. Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer. 2001;92(1):172–80.CrossRef Huang J, Mackillop WJ. Increased risk of soft tissue sarcoma after radiotherapy in women with breast carcinoma. Cancer. 2001;92(1):172–80.CrossRef
21.
go back to reference Mellemkjaer L, Friis S, Olsen JH, Scélo G, Hemminki K, Tracey E, et al. Risk of second cancer among women with breast cancer. Int J Cancer. 2006;118(9):2285–92.CrossRef Mellemkjaer L, Friis S, Olsen JH, Scélo G, Hemminki K, Tracey E, et al. Risk of second cancer among women with breast cancer. Int J Cancer. 2006;118(9):2285–92.CrossRef
22.
go back to reference Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Nat Cancer Inst. 1994;86(7):527–37.CrossRef Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Nat Cancer Inst. 1994;86(7):527–37.CrossRef
23.
go back to reference Liu J, Jiang W, Mao K, An Y, Su F, Kim BYS, et al. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. Breast Cancer Res Treat. 2015;159(2):439–45. Liu J, Jiang W, Mao K, An Y, Su F, Kim BYS, et al. Elevated risks of subsequent endometrial cancer development among breast cancer survivors with different hormone receptor status: a SEER analysis. Breast Cancer Res Treat. 2015;159(2):439–45.
25.
go back to reference Haase D, Hanf V, Schulz T. Therapy-related hematologic neoplasias after breast cancer Epidemiologic, etiologic and cytogenetic aspects and new risk factors according to published data and own results. Med Klin (Munich). 2004;99(9):506–17.CrossRef Haase D, Hanf V, Schulz T. Therapy-related hematologic neoplasias after breast cancer Epidemiologic, etiologic and cytogenetic aspects and new risk factors according to published data and own results. Med Klin (Munich). 2004;99(9):506–17.CrossRef
26.
go back to reference Lai JH, Park G, Gerson LB. Association between BC and the risk of colorectal cancer. Gastrointest Endosc. 2017;86:429–41.CrossRef Lai JH, Park G, Gerson LB. Association between BC and the risk of colorectal cancer. Gastrointest Endosc. 2017;86:429–41.CrossRef
28.
go back to reference Early Breast Cancer Trialists’ Collaborative Group, McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–35.CrossRef Early Breast Cancer Trialists’ Collaborative Group, McGale P, Taylor C, Correa C, Cutter D, Duane F, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014;383(9935):2127–35.CrossRef
29.
go back to reference Boekel NB, Schaapveld M, Gietema JA, Russell NS, Poortmans P, Theuws JC, et al. Cardiovascular disease risk in a large, population-based cohort of breast cancer survivors. Int J Radiat Biol Phys. 2016;94(5):1061–72.CrossRef Boekel NB, Schaapveld M, Gietema JA, Russell NS, Poortmans P, Theuws JC, et al. Cardiovascular disease risk in a large, population-based cohort of breast cancer survivors. Int J Radiat Biol Phys. 2016;94(5):1061–72.CrossRef
30.
go back to reference Dubose AC, Chu QD, Li BD, Kin RH. Is chronic kidney disease an independent risk factor for mortality in breast cancer? J Surg Res. 2013;184(1):260–4.CrossRef Dubose AC, Chu QD, Li BD, Kin RH. Is chronic kidney disease an independent risk factor for mortality in breast cancer? J Surg Res. 2013;184(1):260–4.CrossRef
Metadata
Title
Cause-specific mortality after a breast cancer diagnosis: a cohort study of 10,195 women in Girona and Tarragona
Authors
A. Ameijide
R. Clèries
M. Carulla
M. Buxó
R. Marcos-Gragera
J. M. Martínez
M. L. Vilardell
M. Vilardell
J. A. Espinàs
J. M. Borràs
Á. Izquierdo
J. Galceran
Publication date
01-08-2019
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 8/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-018-02015-5

Other articles of this Issue 8/2019

Clinical and Translational Oncology 8/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine